OncoDiag

Executive Summary

OncoDiag is a French biotechnology company specializing in non-invasive diagnostic tests for early cancer detection and surveillance. Its lead product, Urodiag®, is a CE-IVD marked urine-based test for bladder cancer surveillance, offering a less invasive alternative to cystoscopy. The company was founded in 2015 and is headquartered in Evreux, Normandy. OncoDiag aims to address the growing demand for liquid biopsy solutions in oncology, leveraging its expertise in biomarker discovery and assay development. The Urodiag test has the potential to reduce patient discomfort and healthcare costs while improving surveillance compliance. However, as a private company with limited disclosed financials, its commercial traction and scalability remain unclear. The competitive landscape includes other urine-based tests and emerging liquid biopsy players. Key risks include regulatory changes, market adoption, and reimbursement challenges. OncoDiag's future growth depends on expanding its product pipeline, securing distribution partnerships, and generating clinical evidence to support broader adoption. Despite these uncertainties, the company's focus on bladder cancer—a high-recurrence cancer—positions it in a niche with clear unmet needs.

Upcoming Catalysts (preview)

• Q3 2026CE-IVD renewal or update for Urodiag®85% success
• Q4 2026Clinical study results for Urodiag® in new cancer indication (e.g., other urological cancers)40% success
• TBDCommercial partnership agreement for European distribution50% success